Propranolol for Induction of Labor in Nulliparas trial a double-blind, randomized, placebo-controlled trial

BackgroundPropranolol hydrochloride is a nonselective beta-adrenergic antagonist that has known activity in the myometrium. Small trials have shown propranolol decreases duration of induced labor, although those studies are limited by methodological variability.ObjectiveOur objective was to determine whether addition single dose induce labor nulliparous women would decrease total time vaginal delivery.Study DesignThis study double-blind, randomized, placebo-controlled trial patients undergoing term induction with singleton, nonanomalous gestation. Subjects were randomized 2 mg intravenous or an identical-appearing saline placebo, administered 30 minutes after starting labor. Investigators, floor staff, and blinded drug allocation. The primary outcome delivery. Secondary outcomes included mode delivery, phases full dilation, composite maternal morbidity, neonatal morbidity. Data analyzed intention-to-treat analysis P value ?.05 considered significant.ResultsIn this study, 240 enrolled from December 2017 2018, 121 group 119 placebo group. groups had similar baseline characteristics. Of 154 (64.2%) delivered vaginally. There no significant difference start delivery (13.8±5.4 hours for vs 14.3±5.3 placebo; P=.58). also rate cesarean (38% 33.6%; P=.48), active (11.0±5.0 11.2±4.5 hours; P=.77), dilation (12.4±5.1 12.8±5.2 P=.60) receiving compared placebo. significantly lower morbidity (28.9% 41.2%; risk ratio, 0.70; 95% confidence interval, 0.49–1.00; P=.047). Rates postpartum hemorrhage (12.4% 21.8%; P=.05) transfusion (0% 4.2%; P=.03) treated (risk 0.74; 0.44–1.22).ConclusionIn there evidence 1-time However, reduced without adverse effects. Propranolol variability. Our This significant. In 0.44–1.22).